Relaxin immunoglobulin fusion proteins and methods of use
AssigneeThe Scripps Research Institute
InventorsFeng Wang, Yan Liu, Ying Wang, Guangsen Fu, Peter G. Schultz
Life of this patent
Estimating the term…
Abstract
Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.
Claims22
An antibody comprising a light chain comprising light chain complementarity determining regions CDRL1, CDRL2, and CDRL3, and a heavy chain comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein:
- the CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 89 (KCQLSVGYMH),
- the CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 90 (DTSKLAS),
- the CDRL3 comprises the amino acid sequence of SEQ ID NO:
- 96 (FQGNGYPFT),
- the CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 72 (TFSGFSLSTSGMSVG),
- the CDRH2 comprises the amino acid sequence of SEQ ID NO:
- 73 (DIWWDDKKDYNPSLKS),
- and the CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 79 (SMITFGGFDV).
A composition comprising a first polypeptide comprising a relaxin polypeptide connected to the amino-terminus of a heavy chain antibody variable domain, and a second polypeptide comprising a light chain antibody variable domain, wherein;
- i) the heavy chain variable domain is at least 90% identical to SEQ ID NO:
- 16 and comprises heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein the CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 72 (TFSGFSLSTSGMSVG), the CDRH2 comprises the amino acid sequence of SEQ ID NO:
- 73 (DIWWDDKKDYNPSLKS), and the CDRH3 comprises an amino acid sequence selected from SEQ ID NO:
- 79 (SMITFGGFDV), SEQ ID NO:
- 80 (SMITNAYFDV), and SEQ ID NO:
- 81 (SMITNGYFDV);
- and
- ii) the light chain antibody variable domain is at least 90% identical to SEQ ID NO:
- 12 and comprises light chain complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein the CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 89 (KCQLSVGYMH), wherein the CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 90 (DTSKLAS) and wherein the CDRL3 comprises an amino acid sequence selected from SEQ ID NO:
- 91 (FOGSGYPFT), SEQ ID NO:
- 95 (FOYSGYPFT), and SEQ ID NO:
- 96 (FOGNGYPFT);
- and
- wherein the heavy chain antibody variable domain and the light chain antibody variable domain form an immunoglobulin domain that binds to RSV F protein;
- wherein the relaxin polypeptide comprises a B chain comprising SEQ ID NO:
- 46, and an A chain comprising SEQ ID NO:
- 45.
Dependencies are inferred from the claim text.